ATE541566T1 - Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche - Google Patents

Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche

Info

Publication number
ATE541566T1
ATE541566T1 AT05825944T AT05825944T ATE541566T1 AT E541566 T1 ATE541566 T1 AT E541566T1 AT 05825944 T AT05825944 T AT 05825944T AT 05825944 T AT05825944 T AT 05825944T AT E541566 T1 ATE541566 T1 AT E541566T1
Authority
AT
Austria
Prior art keywords
compositions
ocular
pathologies
methods
eye surface
Prior art date
Application number
AT05825944T
Other languages
English (en)
Inventor
Lionel Bueno
Marie-Therese Droy-Lefaix
Philippe Caron
Original Assignee
Lionel Bueno
Marie-Therese Droy-Lefaix
Philippe Caron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lionel Bueno, Marie-Therese Droy-Lefaix, Philippe Caron filed Critical Lionel Bueno
Application granted granted Critical
Publication of ATE541566T1 publication Critical patent/ATE541566T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
AT05825944T 2004-12-09 2005-12-09 Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche ATE541566T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0413136A FR2879100B1 (fr) 2004-12-09 2004-12-09 Compositions pour le traitement des pathologies oculaires de surface et de la retine
PCT/FR2005/003095 WO2006061525A2 (fr) 2004-12-09 2005-12-09 Compositions pour le traitement des pathologies oculaires de surface

Publications (1)

Publication Number Publication Date
ATE541566T1 true ATE541566T1 (de) 2012-02-15

Family

ID=34954092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05825944T ATE541566T1 (de) 2004-12-09 2005-12-09 Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche

Country Status (10)

Country Link
US (1) US8273708B2 (de)
EP (1) EP1827403B1 (de)
JP (1) JP2008523038A (de)
AT (1) ATE541566T1 (de)
DK (1) DK1827403T3 (de)
ES (1) ES2383758T3 (de)
FR (1) FR2879100B1 (de)
PL (1) PL1827403T3 (de)
PT (1) PT1827403E (de)
WO (1) WO2006061525A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
FR3008698B1 (fr) * 2013-07-18 2016-10-28 Neuroptis Biotech Procede pour la production d'un actif pharmaceutique
FR3022461B1 (fr) * 2014-06-23 2017-11-03 Neuroptis Biotech Methodes therapeutiques et compositions
EP3034081A1 (de) * 2014-12-18 2016-06-22 Neuroptis Biotech Behandlung einer Entzündung der Fußwurzeldrüse des Augenlids

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030631A (en) * 1989-11-27 1991-07-09 Schering Corporation Tricylclic arylsulfonamides
US5189056A (en) * 1989-12-19 1993-02-23 University Of North Carolina At Chapel Hill Protection of moist stratified squamous epithelia against damage from noxious luminal agents
FR2674434B1 (fr) 1991-03-27 1993-06-18 Nativelle Sa Ets Nouvelle composition pharmaceutique a base de taurine pour l'administration par inhalation.
US5336503A (en) * 1992-03-31 1994-08-09 Daiichi Pharmaceutical Co., Ltd. Anti-peptic ulcer agent
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5504098A (en) 1993-02-19 1996-04-02 Asahi Kasei Kogyo Kabushiki Kaisha Benzothiazolesulfonamide derivative, method for preparing the same, and use thereof
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JP3854657B2 (ja) 1996-03-05 2006-12-06 雪印乳業株式会社 腸管保護剤
AU703540B2 (en) 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
RU2148997C1 (ru) 1996-10-01 2000-05-20 Фишер Ольга Алексеевна Способ лечения болевого синдрома
US5912323A (en) 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US20020045564A1 (en) * 1997-06-23 2002-04-18 Van Eyk Jennifer E. Methods of modulating muscle contraction
US6227658B1 (en) * 1997-06-23 2001-05-08 Kabushiki Kaisha Toshiba Apparatus and method for forming thin film using ink-jet mechanism
CA2302782A1 (en) 1997-09-19 1999-03-25 Magainin Pharmaceuticals, Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
NL1011680C2 (nl) 1999-03-26 2000-09-27 Nutricia Nv Voedingssamenstellen die licht negatief geladen, niet-verteerbare polysacchariden bevatten en gebruik ervan voor het verminderen van transport door tight junctions.
MXPA03001468A (es) 2000-08-15 2004-05-04 Immunex Corp Polipeptidos de claudia.
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
AU2002248381A1 (en) 2001-01-25 2002-08-06 Board Of Regents, The University Of Texas System Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics
CA2454976C (en) * 2001-07-26 2011-05-10 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
FR2833840B1 (fr) * 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
JP2005526772A (ja) * 2002-03-15 2005-09-08 リテック 消化機能病理を処置するための組成物
CA2565446A1 (en) 2004-05-05 2005-12-01 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases

Also Published As

Publication number Publication date
PL1827403T3 (pl) 2012-09-28
ES2383758T3 (es) 2012-06-26
US20080139451A1 (en) 2008-06-12
FR2879100B1 (fr) 2007-07-06
WO2006061525A2 (fr) 2006-06-15
EP1827403B1 (de) 2012-01-18
PT1827403E (pt) 2012-04-23
FR2879100A1 (fr) 2006-06-16
JP2008523038A (ja) 2008-07-03
DK1827403T3 (da) 2012-05-07
US8273708B2 (en) 2012-09-25
WO2006061525A3 (fr) 2007-02-22
EP1827403A2 (de) 2007-09-05

Similar Documents

Publication Publication Date Title
ATE254461T1 (de) Behandlung von augenschmerzen
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
TW200733964A (en) (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions
EP1673078A4 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
IL181740A0 (en) THERAPEUTIC AGENTS TARGETING THE NCca-atp CHANNEL AND METHODS OF USE THEREOF
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
DE60309888D1 (de) Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
EA200300560A1 (ru) Улучшенный способ лечения
EA202092225A1 (ru) Соединения и их применение
ATE541566T1 (de) Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche
WO2004091436A3 (en) Methods and compositions for treating ocular disease
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE422944T1 (de) Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs